title: Novel antiplatelet drugs in clinical development.
abstract: The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold promise to improve this benefit-risk ratio.
authors.affiliation: M. Ungerer, Advancecor GmbH, Fraunhofer Str. 17, 82152 Martinsried, Germany, E-mail: ungerer@advancecor.com.
authors.forename: M
authors.initials: M
authors.lastname: Ungerer
authors.forename: G
authors.initials: G
authors.lastname: Münch
mesh_terms: D000818:Animals; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D018570:Risk Assessment
chemical_list: D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D058921:Purinergic P2Y Receptor Antagonists